INmune Bio Inc. - Common stock (NQ:INMB)

1.330 -0.090 (-6.34%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2026 Add to My Watchlist

Price and Volume

Volume	283,874
Open	1.420
Bid (Size)	1.340 (800)
Ask (Size)	1.350 (300)
Prev. Close	1.420
Today's Range	1.320 - 1.420
52wk Range	1.160 - 11.64
Shares Outstanding	17,703,692
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar

February 23, 2026

Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

February 19, 2026

From INmune Bio, Inc.

Via GlobeNewswire

Performance

YTD	-13.6%	-13.6%
1 Month	-13.6%	-13.6%
3 Month	-40.4%	-40.4%
6 Month	-24.4%	-24.4%
1 Year	-83.7%	-83.7%

More News

INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? ↗

February 12, 2026

Via Stocktwits

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease

February 12, 2026

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB

February 10, 2026

From INmune Bio, Inc.

Via GlobeNewswire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

January 27, 2026

From INmune Bio, Inc.

Via GlobeNewswire

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

December 05, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

December 01, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

November 18, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗

October 30, 2025

Via Chartmill

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

October 23, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

October 14, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal

September 29, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

September 15, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio (INMB) Q2 Loss Widens 110% ↗

August 07, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 07, 2025

Via Benzinga

What's going on in today's pre-market session ↗

August 04, 2025

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 04, 2025

Via Benzinga

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 04, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

July 29, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

July 28, 2025

Via Benzinga

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗

July 28, 2025

Via Benzinga

Frequently Asked Questions

Is INmune Bio Inc. - Common stock publicly traded?

Yes, INmune Bio Inc. - Common stock is publicly traded.

What exchange does INmune Bio Inc. - Common stock trade on?

INmune Bio Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for INmune Bio Inc. - Common stock?

The ticker symbol for INmune Bio Inc. - Common stock is INMB on the Nasdaq Stock Market

What is the current price of INmune Bio Inc. - Common stock?

The current price of INmune Bio Inc. - Common stock is 1.330

When was INmune Bio Inc. - Common stock last traded?

The last trade of INmune Bio Inc. - Common stock was at 03/12/26 04:00 PM ET

What is the market capitalization of INmune Bio Inc. - Common stock?

The market capitalization of INmune Bio Inc. - Common stock is 23.55M

How many shares of INmune Bio Inc. - Common stock are outstanding?

INmune Bio Inc. - Common stock has 24M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.